Sandi See Tai
About Sandi See Tai
Sandi See Tai, M.D., is Lexeo Therapeutics’ Chief Development Officer (CDO), serving since February 2024 after leading Clinical Development and Operations as SVP from October 2023 to February 2024. She is 54 years old and previously held senior development leadership roles at Pfizer, with earlier medical affairs roles at Wyeth, and academic/clinical positions at Drexel University College of Medicine and St. Christopher’s Hospital for Children; the proxies do not disclose individual TSR or financial performance metrics tied to her compensation . Her background spans rare disease portfolio strategy, clinical development execution, and pediatric nephrology, including residency and fellowship completions prior to entering industry .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Lexeo Therapeutics | SVP, Clinical Development & Operations | Oct 2023–Feb 2024 | Led clinical development and operations before promotion to CDO |
| Pfizer Inc. | VP & Development Head, Rare Diseases | Aug 2022–Jun 2023 | Set rare disease internal portfolio and BD strategy; delivered clinical portfolio |
| Pfizer Inc. | VP & Medicine Team Lead (Rare Neuroscience, Amyloid, Rare Cardiac, Renal, Pulmonary) | Apr 2010–Aug 2022 | Led multiple therapeutic area teams and programs within Pfizer |
| Wyeth Pharmaceuticals (acquired by Pfizer) | Global Medical Affairs – Transplantation | Sep 2004–Mar 2010 | Medical affairs roles across transplantation therapies |
| Drexel University College of Medicine | Assistant Professor of Pediatrics | 2001–2004 | Academic teaching and research in pediatrics |
| St. Christopher’s Hospital for Children | Attending Physician, Pediatric Nephrology | 2001–2005 | Clinical practice; completed pediatric residency (1998) and nephrology fellowship (2001) |
External Roles
No external public-company directorships or committee roles for Dr. See Tai are disclosed in the 2024 or 2025 proxy statements; the executive officer biographies list none .
Fixed Compensation
- Dr. See Tai was not a Named Executive Officer (NEO) in FY2023 or FY2024; therefore, base salary, target bonus, and actual bonus figures were not reported in the Summary Compensation Tables for those years .
Performance Compensation
- The proxies do not disclose performance-based incentive metrics, payouts, or grant details specific to Dr. See Tai (she was not an NEO in FY2023–2024); company-level executive award disclosures pertain to other named officers only .
Equity Ownership & Alignment
- Beneficial ownership tables list directors and NEOs; Dr. See Tai is not included, so her total beneficial ownership, vested/unvested breakdown, and options status are not disclosed in the 2024 or 2025 proxies .
- Hedging/pledging is prohibited for all employees and directors under Lexeo’s Insider Trading and Window Period Policy, mitigating alignment risks from derivative or margin strategies .
- In the October 2025 financing, officers and directors entered lock-up agreements restricting offers, sales, pledges, and hedging of company securities for 60 days after the final prospectus, with limited carve-outs (e.g., tax withholding, estate transfers, pre-existing 10b5-1 plans) .
Employment Terms
- The proxies do not disclose an individual employment agreement, severance, or change-of-control provisions for Dr. See Tai; comparable terms are disclosed for certain other executives only .
- Indemnification: Lexeo has indemnification agreements with each director and executive officer, requiring indemnification to the fullest extent permitted by Delaware law .
- Insider trading policies and award timing practices are described, including prohibitions on hedging/pledging and no timing of grants around MNPI; these policies apply broadly to officers and employees .
Investment Implications
- Disclosure gap: As Dr. See Tai was not an NEO in FY2023–2024, investors lack visibility into her cash/equity pay mix, performance metrics, and severance/CIC terms—monitor subsequent proxies and any Item 5.02 8-Ks for updates .
- Alignment safeguards: Company-wide prohibitions on hedging/pledging and periodic financing lock-ups for officers reduce near-term selling pressure and misalignment risk, supporting retention and long-term focus .
- Role significance: As CDO, her remit over rare disease clinical portfolio execution is strategically central; but without Form 4 visibility in the toolset and absent ownership disclosures, trading-pressure signals and skin-in-the-game cannot be assessed—watch future Form 4s and beneficial ownership updates .
- Governance baseline: Indemnification is in place; say-on-pay items were not presented in the 2024 AGM 8-K (only director election and auditor ratification), so shareholder feedback on pay practices is unavailable—continue to track annual meeting agendas and outcomes .